Skip to main content

Table 1 Baseline characteristics, comorbidities, laboratory and Step II treatment parameters of 124 patients: odds ratios for risk of XDR-PA colonisation

From: Clinical and treatment-related risk factors for nosocomial colonisation with extensively drug-resistant Pseudomonas aeruginosa in a haematological patient population: a matched case control study

Parameter

Cases (n = 31)

Controls (n = 93)

Crude OR (95% CI)

P-value

Basic parameters

Age, median (IQR), years

56 (48–68)

60 (51–70)

0.9835 (0.9539 - 1.0141)‡

0.28

Female sex, %

11 (35.5%)

20 (21.5%)

1.19 (0.53 - 2.65)

0.68

Admission from home, %

26 (83.9%)

83 (89.3%)

0.61 (0.18 - 2.01)

0.42

Stay on ICU, %

12 (38.7%)

25 (26.9%)

6.23 (1.16 - 33.4)

0.024

Length of ICU stay, mean (range), days

10.58 (0–71)

9.66 (0–80)

1.0055 (0.9747 - 1.0374)‡

0.73

Time at risk > 14 days, %

19 (61.3%)

39 (41.9%)

2.54 (1.01 - 6.34)

0.04

IDNPA, %

17 (54.8%)

20 (21.5%)

5.47 (1.95 - 15.37)

0.0004

Comorbid conditions

Immune suppression, %

30 (96.8%)

79 (85%)

5.35 (0.67 - 42.5)

0.05

Charlson Comorbidity Score, median (IQR)

2 (2–4)

2 (2–4)

1.13 (0.91 - 1.41)

0.28

Diabetes, %

5 (16.1%)

16 (17.2%)

0.92 (0.3 - 2.8)

0.89

Cardiovascular disease, %

15 (48.4%)

37 (39.8%)

1.44 (0.62 - 3.3)

0.4

Patient’s clinical record

SAPS II, mean (range)

27.97 (13–44)

26.32 (6–51)

1.0234 (0.9752 - 1.074)‡

0.35

Neutropenia (<1000 cells/μl), %

22 (71%)

51 (54.8%)

2.13 (0.86 - 5.31)

0.095

Length of Neutropenia, median (IQR), days

9 (0–18)

2 (0–16)

1.0239 (0.9897 - 1.0592)‡

0.17

Non-invasive ventilation, %

9 (29%)

24 (25.8%)

1.2 (0.46 - 3.13)

0.71

CVC, %

21 (67.7%)

40 (43%)

3.48 (1.35 - 9)

0.008

Length of CVC, mean (range), days

14.13 (0–59)

11.13 (0–86)

1.0155 (0.9867 - 1.0452)‡

0.3

Urinary catheter, %

13 (41.9%)

8 (8.6%)

6.75 (2.38 - 19.17)

0.0001

Length of urinary catheter, mean (range), days

4.03 (0–20)

0.98 (0–23)

1.1159 (1.0266 - 1.2129)‡

0.005

Room preoccupied by case (30 days), %

4 (12.9%)

7 (7.5%)

1.46 (0.48 - 8.4)

0.35

Room preoccupied by case (6 weeks), %

4 (12.9%)

9 (9.7%)

1.41 (0.38 - 5.22)

0.61

Most pathological laboratory parameter during time at risk

White blood cell count, median (IQR), cells/μl

1260 (330–3170)

2060 (360–5720)

0.99998 (0.99993 - 1.00004)‡

0.73

Neutrophils, median (IQR), cells/μl

320 (20–1076)

1090 (50–3383)

0.9999 (0.9998 - 1)‡

0.14

Platelet count < 50,000 cells/μl, %

21 (67.7%)

44 (47.3%)

2.55 (1.04 - 6.28)

0.04

Creatinine, median (IQR), mg/dl

1.1 (0.8 - 1.4)

1 (0.8 - 1.2)

1.27 (0.85 - 1.88)‡

0.24

CRP > 10 mg/dl, %

21 (67.7%)

32 (34.4%)

5.29 (1.88 - 14.89)

0.0005

Step II treatment variables*

Cases (n = 31)

Controls (n = 93)

OR (95% CI)

P-value

Ceftazidime use, %

10 (32.3%)

5 (5.4%)

4.28 (0.74 - 24.77)

0.09

Ciprofloxacin use, %

8 (25.8%)

11 (11.8%)

5.53 (1.11 - 27.53)

0.025

NDA > 3, %

20 (64.5%)

27 (29%)

4.35 (0.87 - 21.68)

0.06

  1. ‡Per 1 unit increase.
  2. *All antibiotics with a P < 0.1 in the Step II models are listed.
  3. XDR-PA, extensively drug-resistant Pseudomonas aeruginosa; IQR, interquartile range; ICU, intensive care unit; IDNPA, infectious diseases not caused by Pseudomonas aeruginosa; SAPS II, Simplified Acute Physiology Score II; CVC, central venous catheter; CRP, C-reactive protein; DDD, defined daily dose; NDA, number of different antibiotics during time at risk; 95% CI, 95% confidence interval.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us